Associated Papers
The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.
Sun J et al.
Frontiers in Endocrinology, 2024
Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
Hao S et al.
Cancer Medicine, 2023
Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease.
Cavalcante IP et al.
Nature Reviews. Endocrinology, 2022
Functional characteristics and research trends of PDE11A in human diseases (Review).
Kong G et al.
Molecular Medicine Reports, 2022
A Gene-Based Classification of Primary Adrenocortical Hyperplasias.
Hannah-Shmouni F et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 2020
Alterations of Phosphodiesterases in Adrenocortical Tumors.
Hannah-Shmouni F et al.
Frontiers in Endocrinology, 2016
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Pathak A et al.
Endocrine-related Cancer, 2015
Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition.
Azevedo MF et al.
The Journal of Clinical Endocrinology and Metabolism, 2013
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.
Vezzosi D et al.
The Journal of Clinical Endocrinology and Metabolism, 2012
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Almeida MQ et al.
Molecular and Cellular Endocrinology, 2011
Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.
Faucz FR et al.
The Journal of Clinical Endocrinology and Metabolism, 2011
Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.
Libé R et al.
The Journal of Clinical Endocrinology and Metabolism, 2011
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Peverelli E et al.
European Journal of Endocrinology, 2009
Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.
Hsiao HP et al.
The Journal of Clinical Endocrinology and Metabolism, 2009
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Horvath A et al.
Cancer Research, 2009
New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors.
Stratakis CA
Molecular and Cellular Endocrinology, 2009
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Libé R et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.
Boikos SA et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 2008
Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias.
Stratakis CA et al.
Nature Clinical Practice. Endocrinology & Metabolism, 2007
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
Horvath A et al.
Cancer Research, 2006
A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia.
Horvath A et al.
Nature Genetics, 2006
Genetics of primary macronodular adrenal hyperplasia.
Candida Barisson Villares Fragoso M et al.
Presse Medicale (paris, France : 1983), 0